Risk factors

LeonaBio (LONA) risk factors

Item 1A of every LeonaBio, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open LONA in Gloom →
LeonaBio's chart, financials and news, free in your browser.Open LONA in Gloom →
  • FY2025 10-K risk factors
    105 risks17 new17 dropped23 reworded

    LeonaBio acquired exclusive rights to develop and commercialize lasofoxifene from Sermonix and Ligand, shifting its strategic focus.

    Filed Mar 31, 2026
  • FY2024 10-K risk factors
    105 risks

    LeonaBio is a clinical-stage biopharmaceutical company focused on neurodegeneration, dealing with the clinical development of ATH-1105 after halting fosgonimeton due to failed Phase 2/3 trial results.

    Filed Feb 27, 2025